^
Association details:
| Biomarker: | NRAS Q61 |
|---|---|
| Cancer: | Melanoma |
| Drug: | Cotellic (cobimetinib) (MEK1 inhibitor) + Daliresp (roflumilast) (PDE4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combined PDE4+MEK inhibition shows antiproliferative effects in NRASQ61 mutated melanoma preclinical models
Published date:
12/22/2023
Excerpt:
In this study, we generated patient-derived xenografts (PDX) from two NRASQ61mut melanoma lesions. We performed ex vivo histoculture drug response assays and in vivo experiments. A significant ex vivo inhibition of proliferation with the combination of roflumilast+cobimetinib was observed compared to dimethyl sulfoxyde control in both models (51 and 67%). This antiproliferative effect was confirmed in vivo for PDX-1 with a 56% inhibition of tumor growth.
DOI:
10.1097/CMR.0000000000000950
